The global patient mortality rate of COVID-19 was 3-4% of confirmed cases in 2020 since the outbreak first began. The response of the immune system may play a critical role in the disease progression, severity, and mortality of COVID-19, with some studies showing decreased T cells and natural killer cells in patients infected with SARS-CoV-2, the virus responsible for COVID-19.
Professor Dexi Chen, the Director of the Beijing Institute of Hepatology, investigated the immune system of patients suffering from severe COVID-19. The study uncovered a decreased proportion of T-cells and downregulation of genes related to T-cell activation and differentiation in severe COVID-19 patients.
This information may help researchers understand the immune response to COVID-19 and inform treatment strategies for the disease.
In this webinar, you will discover:
For Research Use Only. Not For Use In Diagnostic Procedures.
Prof. Dexi Chen
Beijing Institute of Hepatology
Professor and Director
Prof. Dexi Chen is the Director of the Beijing Institute of Hepatology since 2010, mainly focused on the molecular and cellular biology of infectious diseases, and the mechanisms of hepatocarcinogenesis induced by HBV. Previously, Prof. Chen led the HIV research lab at You`an hospital with his team publishing more than 70 papers. For his outstanding contributions, Prof. Chen has received numerous honors including the State Council Special Allowance Award, the 2nd prize of Chinese Medical Science, and the Technology Award.
Session 1:presented September 21, 2020
To continue reading please sign in or create an account.Don't Have An Account?